Supplement 2 Candidate risk factors for the study
Definitions
Comorbidity
Arrhythmia
Heart valve disease
Cardiac
Hepatic
Renal
Hypertension
Diabetes
Prior solid tumor
Cerebrovascular disease
Chronic lung disease
Atrial fibrillation or flutter; sick sinus syndrome
Except mitral valve prolapse
Coronary artery disease; congestive heart failure; or EF≦50%
Mild: Chronic hepatitis, bilirubin>ULN to 1.5×ULN;
Moderate/severe: Liver cirrhosis, bilirubin >1.5 ×ULN;
Mild: Serum creatinine﹥ULN to 2mg/dL;
Moderate/severe: Serum creatinine>2mg/dL, on dialysis, or prior
renal transplantation
Mild: Grade 1 hypertension, and requiring treatment with
antihypertensive agent;
Moderate/severe: ≧Grade 2 hypertension, and requiring treatment
with antihypertensive agent;
Mild: Requiring treatment with insulin or oral hypoglycemics but
not diet alone;
Moderate/severe: Diabetes target organ damage happened (such as
Diabetic nephropathy, Diabetic retinopathy, Diabetic foot, etc.)
Treated at any time point in the patient’s past history, excluding
nonmelanoma skin cance;
Transient ischemic attack ; stroke;
Chronic obstructive pulmonary diseases; Chronic bronchitis;
Silicosis;
60years;
>60years;
Requiring continuation of antimicrobial treatment after day 0 of
chemotherapy because of confirmed or suspected infection, but not
prophylactic anti-infective therapy;
Age
Infection
abnormalities
Plasma fibrinogen 1.5g/L;
Intensity of chemotherapy
See detail in Supplement 3;
Acute leukemia
No: Chronic leukemia, Lymphoma, Multiple myeloma,
Myelodysplastic syndrome;
Yes: Acute myelocytic leukemia, Acute lymphoblastic leukemia,
Chronic leukemia blastic phase, Plasma cell leukemia;
Men;
Women;
Patients with a body mass index>24 kg/m2;
Coagulation
Gender
Obesity